Heart Failure Clinical Trial

Tele-HF: Yale Heart Failure Telemonitoring Study

Summary

The primary purpose of this study is to determine the effectiveness of telemonitoring compared with usual guideline-based care in preventing hospitalization for heart failure patients.

View Full Description

Full Description

Heart failure (HF) is a common, costly condition characterized by recurrent periods of clinical decompensation that often lead to repeated hospitalizations (1, 2). Despite advances in the care of patients with HF, population-based outcomes such as mortality and hospitalization rates have not improved substantially over the past decade (3). Episodic, infrequent, outpatient visits are the only usual opportunities for clinicians to detect and treat early signs of HF decompensation; this constitutes a major gap in the current medical model. Moreover, opportunities for patients to take an active role in managing their own conditions occur infrequently. Disease management has emerged as a possible solution to the need for better patient surveillance and engagement. It typically involves multidisciplinary efforts to improve the quality and efficiency of care for patients with chronic conditions, with interventions designed to foster adherence of clinicians to scientific guidelines and patients to treatment plans. However, traditional disease-management programs are generally resource-intensive (often relying on nurse case management), difficult to scale for a large population, and inefficient in providing daily patient monitoring.

Telemonitoring, which bridges clinicians and patients with communication technology, holds promise for closing the gap in HF care (4). This technology has the potential for standardized, widespread implementation (and long-term maintenance) in the near future because it can be easily applied to large patient populations and integrated into the current medical care system. Supporting this potential, preliminary evaluations have suggested that telemonitoring is feasible across a broad spectrum of typical HF patients, relatively inexpensive on a per-patient basis, and highly effective in improving health outcomes. Thus, this approach is ready for rigorous evaluation.

Accordingly, we propose an office-based, multicenter, randomized controlled trial (Tele-HF study) to determine the effectiveness of a telemonitoring strategy in decreasing hospital readmissions and death in patients with HF. Many HF patients experience deterioration in their health status and an increase in weight and symptoms over a period of days and weeks before ultimately presenting to medical attention and requiring hospitalization. Our premise is that a frequent monitoring system can alert clinicians to the early signs and symptoms of decompensation, providing the opportunity for intervention before the patient becomes severely ill and requires hospitalization. Moreover, such a system can engage patients in their care and provide instruction about beneficial self-care strategies. This intervention is not intended to substitute for communication relating to acute care or acute, sudden changes in health status. In these cases, patients are instructed to make direct and immediate contact with their doctor or hospital.

We will use the Pharos Tel-AssuranceTM, an in-home communication system that allows patients to transmit information to their clinicians and provides education to enable patients to actively participate in managing their condition. The system uses conventional telephone lines and does not require the patient to have Internet access. Patients are asked a pre-programmed series of questions and the system automatically uploads the responses to a secure data center. A clinician in each practice can then log on to a secure Internet site using a Web browser to review the patients' responses. The system thus serves as an interface between patients at home and their clinicians, facilitating monitoring of chronic conditions and patient education. While many vendors have potential tools to implement this study, we chose to use Pharos Tel-AssuranceTM because it is simple to use, does not require any equipment in patients' homes and substantial preliminary data suggest high patient and clinician satisfaction with its use. The investigators have no financial interest in this company.

Primary Aim Our primary aim is to determine whether telemonitoring by community-based cardiology office practices reduces the risk of hospital readmission (for any cause) or death after an initial "index hospitalization" for HF. We hypothesize that, among patients recently discharged after a hospitalization for HF, telemonitoring will decrease the rate of rehospitalization or death over 6 months by at least 15% (relative risk reduction). This would yield an absolute risk reduction of 7.5%, so that 1 major adverse event would be averted for every 13 patients.

We have chosen all-cause readmission as part of our primary outcome because poorly controlled HF can result in admissions for a variety of reasons, as the patient becomes weak and susceptible to falls, mental status changes, renal dysfunction, and other debilitating conditions that can result in hospitalization. In addition, from a societal and health system perspective, the overall risk of readmission is more important than disease-specific readmission. Moreover, prior studies suggest that telemonitoring can reduce this outcome.

Secondary Aims

In our secondary aims we will determine whether telemonitoring will:

Reduce the rate of all-cause hospital readmission
Reduce the rate of hospital readmission for HF
Reduce the total number of all-cause and HF-specific hospital readmissions
Increase office visits with the clinician receiving information from the telemonitoring system
Improve survival after index hospitalization
Reduce the cost of inpatient medical care
Improve health status
Improve patient satisfaction with care
Improve patients' self-management of HF

Sub-Group Analyses

The following sub-group analyses will be conducted:

Age
Sex
Race
HFPEF vs depressed EF
Education
Insurance status
Self-reported access to care
Baseline self-efficacy and self-care
Socioeconomic Status
Site characteristics

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

age 18 years or older
hospitalized for heart failure within the past 30 days
access to telephone line

Exclusion Criteria:

not expected to survive 6 months due to irreversible, life-threatening condition
has or scheduled for cardiac transplant or LVAD
scheduled for CABG or PCI within 90 days
severe valvular disease
Folstein MMSE score less than 20
resident of a nursing home
currently a prisoner
does not speak English or Spanish

Study is for people with:

Heart Failure

Estimated Enrollment:

1660

Study ID:

NCT00303212

Recruitment Status:

Completed

Sponsor:

Yale University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 32 Locations for this study

See Locations Near You

Cardiology Associates
Mobile Alabama, 36608, United States
UC Irvine Medical Center
Orange California, 92868, United States
UCLA Harbor Medical Center
Torrance California, 90502, United States
Department of Cardiology at Bridgeport Hospital
Bridgeport Connecticut, 06610, United States
Cardiology Associates of New Haven
New Haven Connecticut, 06437, United States
Howard University Hospital
Washington District of Columbia, 20059, United States
Integrated Care / Cardiovascular Consultants of South Florida
Tamarac Florida, 33321, United States
Piedmont Hospital Research Institute
Atlanta Georgia, 30309, United States
Morehouse School of Medicine/Cardiology
Atlanta Georgia, 30310, United States
Emory University
Atlanta Georgia, 30322, United States
The Queen's Medical Center
Honolulu Hawaii, 96813, United States
Loyola University Medical Center
Maywood Illinois, 60153, United States
Indiana Heart Physicians
Indianapolis Indiana, 46237, United States
Iowa City Heart Center
Iowa City Iowa, 52245, United States
Chabert Medical Center
Houma Louisiana, 70363, United States
Heart Clinic of Louisiana
Marrero Louisiana, 70072, United States
Cardiology Associates, LLC
Tupelo Mississippi, 38801, United States
Truman Medical Center/Cardiology
Kansas City Missouri, 64108, United States
St. Luke's Hospital / Mid-America Heart Institute
Kansas City Missouri, 64111, United States
Washington University
Saint Louis Missouri, 63110, United States
Cardiology Diagnostics
Saint Louis Missouri, 63122, United States
Cooper Health System Cardiology
Camden New Jersey, 08103, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
St. Joseph's Regional Medical Center / Cardiology Associates
Paterson New Jersey, 07503, United States
New York University/Cardiology
New York New York, 10016, United States
Forsyth Medical Center
Winston-Salem North Carolina, 27103, United States
MetroHealth Medical Center, Heart & Vascular Center
Cleveland Ohio, 44109, United States
The Dayton Heart Center
Dayton Ohio, 45414, United States
Oregon Health and Science University
Portland Oregon, 97239, United States
University of Pittsburgh
Pittsburgh Pennsylvania, 15260, United States
Cardiology Specialists, Ltd.
Westerly Rhode Island, 70363, United States
Baylor University Medical Center
Dallas Texas, 75246, United States
Sentara Cardiology Consultants, Ltd.
Norfolk Virginia, 23507, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

1660

Study ID:

NCT00303212

Recruitment Status:

Completed

Sponsor:


Yale University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider